Sign in
4

Changes in Ownership

Aligos Therapeutics, Inc. Filed Acc 0001610717-24-000098

Options or other derivatives

  • Chief Executive Officer acquired 421,100 shares (grant or award)
  • Chief Executive Officer returned 854,250 shares (to the company)

From the SEC's structured data for this filing

Trades in this filing

BLATT LAWRENCE · Chief Executive Officer

Table II: Derivative

6 lines
Date Transaction Shares Owned after D/I
2024-02-27 Returned to the company : show line 1 in the form Stock Option (Right to Buy) −450,000 0 D
2024-02-27 Returned to the company : show line 2 in the form Stock Option (Right to Buy) −323,400 0 D
2024-02-27 Returned to the company : show line 3 in the form Stock Option (Right to Buy) −80,850 0 D
2024-02-28 Grant or award : show line 4 in the form Stock Option (Right to Buy) +132,352 132,352 D
2024-02-28 Grant or award : show line 5 in the form Stock Option (Right to Buy) +230,999 230,999 D
2024-02-28 Grant or award : show line 6 in the form Stock Option (Right to Buy) +57,749 57,749 D
Loading xslF345X05/form4.xml…